Can weaker lung cancer patients handle the same powerful treatment?
NCT ID NCT04253964
First seen Mar 23, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study looks at whether people with advanced non-small cell lung cancer who are in poorer health (performance status 2) can benefit from the same first-line chemo/immunotherapy as those in better health. About 105 participants will be treated and followed to compare cancer progression, survival, side effects, and quality of life. The goal is to see if the treatment is safe and effective for a wider range of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27105, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.